Although the pro- or anti-tumoral role of ILC3 appears to be tumor/model-dependent, a CD56+ /ILC3 subset has been identified in tumor-draining lymph nodes and tumor samples from breast cancer patients with advanced disease [12, 42]. Here, NCAM1 is linked to neoplasm.